Company news

Biovica International AB news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement from the Annual General Meeting in Biovica International AB

September 16, 2026

Biovica Resolves on a Fully Guaranteed Rights Issue of SEK 29.2 Million

September 9, 2026

Biovica Announces Planned CEO Succession; Anders Rylander to Step Down During 2026

March 5, 2026

Biovica Signs Client Bill Agreement with Leading U.S. NCI-Designated Cancer Center

December 15, 2025

Biovica Carries Out a Directed Share Issue of Approximately MSEK 42.2

August 13, 2025

Biovica announces outcome of rights issue

August 5, 2025

Biovica Launches DiviTum(R) TKa for Use in Early Breast Cancer

July 25, 2025

Biovica Awarded 3 MSEK Contract - 4th from Leading Tier-1 Pharma Company

July 24, 2025

Biovica Granted New European Patent

June 26, 2025

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

June 11, 2025

Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress

June 10, 2025

Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value

June 10, 2025

New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types

May 23, 2025

Biovica Signs Major Service Agreement and First Study Work Order of 4 MSEK

May 19, 2025

Biovica Collaborates with Tempus to Expand the Commercial Reach of DiviTum(R) TKa

May 13, 2025

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.